Greenstone Biosciences announced a strategic collaboration with Intel to accelerate AI-enabled drug discovery using Greenstone’s large-scale human biobank of induced pluripotent stem cells and Intel’s Edge AI computing and AI infrastructure.
The collaboration combines Greenstone’s human genetics and biology capabilities with Intel’s purpose-built silicon to scale data processing, storage, and analysis. Greenstone said it has built the world’s largest human biobank of induced pluripotent stem cells.
The companies are working together to speed up the development of new medicines by combining human iPSC biology with advanced computing infrastructure. The collaboration is intended to accelerate drug discovery, improve drug safety, and advance precision medicine.
Greenstone and Intel said the collaboration supports momentum around New Approach Methodologies, which are designed to complement traditional animal studies and improve the translational relevance of preclinical testing. By combining human cellular models, population-scale datasets, and AI-enabled analytics, the companies aim to support the next generation of drug safety assessment and medicine development.
Greenstone Biosciences is a biotechnology company based in Stanford Research Park and co-founded by Joseph C. Wu, M.D., Ph.D., Professor and Director of the Stanford Cardiovascular Institute. The company specializes in New Approach Methodologies, clinical genomics, iPSC platforms, artificial intelligence and machine learning, and drug development.
KEY QUOTE:
“This collaboration represents an important step toward more human-centered drug development. By combining our iPSC-based systems with Intel’s advanced computing architecture, we identify patient-specific response patterns, improve prediction of adverse drug effects, and advance new medicines more quickly and at a lower cost.”
Joseph C. Wu, M.D., Ph.D., Co-Founder of Greenstone Biosciences and Director of the Stanford Cardiovascular Institute
